CN-122005575-A - Composition for treating rheumatoid arthritis and application thereof

Abstract

The invention relates to a composition for treating rheumatoid arthritis and application thereof, belonging to the technical field of medicines. The technical problem to be solved is to provide a composition for treating rheumatoid arthritis, which has better effect and low cost in treating rheumatoid arthritis. The technical scheme is that the composition for treating rheumatoid arthritis consists of cannabidiol and methotrexate.

Inventors

• XIAO CHENG
• XU JIAHE
• DENG TINGTING
• Geng Qishun

Assignees

• 中日友好医院(中日友好临床医学研究所)

Dates

Publication Date

20260512

Application Date

20260403

Claims (10)

1. 1. A composition for the treatment of rheumatoid arthritis, comprising cannabidiol and methotrexate.
2. 2. The composition of claim 1, wherein the mass ratio of cannabidiol to methotrexate in animal experiments is 6.25-25:1.
3. 3. The composition of claim 2, wherein the concentration ratio of cannabidiol to methotrexate in a cellular assay is 25-100:1.
4. 4. Use of a composition according to any one of claims 1 to 3 for the preparation of a medicament for the treatment and/or prophylaxis of rheumatoid arthritis.
5. 5. The use of claim 4, wherein the composition reduces the extent of knee joint swelling.
6. 6. The use according to claim 4, wherein the composition reduces inflammatory factor content in serum.
7. 7. The use of claim 6, wherein the inflammatory factor comprises at least one of TNF- α, IL-1β, and IL-6.
8. 8. The use according to claim 4, wherein the medicament further comprises pharmaceutically acceptable excipients.
9. 9. The use according to claim 8, wherein the adjuvant comprises one or more of diluents, surfactants, wetting agents, lubricants, fillers, disintegrants, coating agents and binders.
10. 10. The use according to claim 4, wherein the pharmaceutical is in the form of a tablet, capsule, granule, pill, emulsion, suspension, solution or syrup.

Description

Composition for treating rheumatoid arthritis and application thereof Technical Field The invention belongs to the technical field of medicines, and particularly relates to a composition for treating rheumatoid arthritis and application thereof. Background Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized mainly by joint synovitis, and pathological changes include joint synovitis cell proliferation, inflammatory cell infiltration, pannus formation and the like, and gradually causes joint cartilage and bone destruction, finally causes joint deformity and loss of function, has no specific therapy so far, and seriously affects the physical function and life quality of patients. Methotrexate (MTX) is an antifolate antineoplastic agent, and is also commonly used in clinic for treating RA, and has the effects of anti-inflammatory, detumescence, pain relief and the like. However, research indicates that the long-term use of methotrexate can generate obvious adverse reaction, damage liver and kidney functions of patients, and has the defect of slow effect when being taken orally, so that the search for safer and more effective drugs is still a problem to be solved in RA treatment, and the combined use of the methotrexate and other drugs is one of the preferred strategies for treating RA. The related patent application documents: The Chinese medicine composition is prepared from 2-4 parts of methotrexate and 50-80 parts of traditional Chinese medicine composition, wherein the traditional Chinese medicine composition comprises radix scutellariae, white paeony root, chinese starjasmine stem and caulis sinomenii according to the weight ratio of 10-15:30-40:10-15:5-15, and the composition provided by the invention takes the methotrexate as a basic component and can inhibit the nephrotoxicity of the methotrexate after adding the white paeony root, and three traditional Chinese medicines of caulis sinomenii, radix scutellariae and caulis sinomenii have the effects of dispelling wind, dredging collaterals and cooling blood to reduce swelling. The methotrexate, the white paeony root, the caulis sinomenii, the baical skullcap root and the collaterals Dan Tengxiang are compounded, so that the rheumatoid arthritis can be effectively treated. The prior art represented by the foregoing documents has at least the following technical problems or drawbacks that have not been solved: The composition of the invention has poor effect on treating rheumatoid arthritis, complex composition components and high production cost. The relevant evidence is that in the mouse experiments, the swelling rate of the test group in table 1 to mice is not high, only 12.82%, and the arthritis score is high, 4.5. Cannabidiol (CBD) is a non-addictive active ingredient in cannabis and has various pharmacological activities such as antispasmodic, anti-inflammatory, anxiolytic, etc. The CBD has good safety, can avoid the influence of Tetrahydrocannabinol (THC) on the nervous system of human body, and has good effects of anti-emetic, anti-inflammatory, analgesic, immunoregulation and the like in various diseases such as cancer, arthritis, epilepsy, multiple sclerosis and the like. Numerous studies have demonstrated that CBD can inhibit proliferation, invasion and migration of tumor cells, and induce apoptosis and autophagy. The prior art has not disclosed that methotrexate and cannabidiol can be used synergistically to treat rheumatoid arthritis. Disclosure of Invention The invention aims to provide that: the composition for treating the rheumatoid arthritis and the related technology thereof are used for solving the technical problems of better effect, low cost and the like or the combination thereof for treating the rheumatoid arthritis. Description of the terminology: Unless defined otherwise, all technical and scientific terms of the invention have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs. All patents, patent inventions, and publications cited herein are incorporated by reference in their entirety unless otherwise indicated. If the present invention has multiple definitions for terms, the definitions of this chapter shall control. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the subject matter of the invention, as claimed. In the present invention, the singular is used to include the plural unless specifically stated otherwise. It should also be noted that the use of "or" means "and/or" unless stated otherwise. Furthermore, the terms "include," as well as other forms, such as "comprising," "including," and "containing," are not limiting. The definition of standard chemical terms can be found in the reference "[ pharmacopoeia of the people's republic of China (2020 edition), chinese medical science and technology Press, month 5 of 2020